Saba's four-fund push dominates the July 28–August 4 whale tape (2026)

The clearest signal in this week's disclosure window was not a broad sector rotation. It was Saba Capital showing up across four closed-end fund situations, with two filings tied to open-market buying and two tied to activism or structure. Around that core, the tape added a debt-to-equity conversion, a merger-linked royalty position, and several passive biotech ownership maps.

Data cutoff: disclosures that became available from July 28 at 8:00 a.m. through August 4 at 8:00 a.m. Central time. Filing-availability dates, transaction/event dates, and position-measurement dates are kept separate below. This is a recap of public disclosures, not a recommendation to copy any position.

What actually changed

1. Saba built a cluster, but the four filings do not mean four fresh weekly buys

Rank	Ticker / filer	What the filing says	Directional read
1	ECAT — Saba Capital (Schedule 13D/A)	Saba and affiliates reported 15,798,219 shares, or 15.88%, with approximately $234.85 million paid. The filing covers open-market transactions from July 22–31, and became available on August 3.	Cleanest accumulation signal in the cluster. The filing's ownership percentage uses ECAT's December 31, 2025 share count, so the current percentage could differ.
2	IIF — Saba Capital (Schedule 13D/A)	Saba reported 853,694 shares, or 9.04%, with approximately $22.21 million paid. The disclosed open-market transaction period runs from March 24 through July 28; the amendment became available July 30.	Accumulation, but not a one-week trade. July 28 is the latest disclosed transaction date; the aggregate cost spans a much longer build.
3	BPRE — Saba Capital (Schedule 13D)	Saba disclosed 7,201,382 shares, or 5.03%, at an approximate aggregate cost of $106.37 million. The July 30 filing says the shares were acquired because Saba believes they are undervalued and leaves open discussions about governance, board appointments, the discount to NAV, liquidation, shareholder proposals, director nominations, and proxy solicitation.	Activist optionality. The filing establishes a meaningful position and a broad menu of possible pressure points; it does not by itself prove a new purchase on July 30.
4	ASA — Saba Capital (Schedule 13D/A)	Saba reported 5,903,701 shares, or 32.16%, at an approximate aggregate cost of $173.27 million. The filing says there were no ASA share transactions in the prior 60 days. Separately, Saba enhanced its July 30 restructuring proposal to contemplate a private-credit manager as subadviser if ASA is converted into a BDC.	Control and structure signal, not fresh buying. The important change is the proposed operating model, not a new cash deployment.

The mistake to avoid is adding the four aggregate costs and calling the result this week's inflow. ECAT and the latest IIF activity are the strongest trade evidence; BPRE is a newly disclosed activist stake; ASA is mainly a governance and restructuring event. Together, however, they do point to a coherent theme: Saba is treating discounts and fund structure as the trade, not simply picking another operating-company stock.

2. The rest of the tape was heavy on special situations and ownership maps

Ticker / filer	Disclosure	How to read it
UUU — Ault (Schedule 13D/A)	Ault's group reported 1,104,052 shares, or 35.9%. Ault Lending listed 385,252 open-market shares purchased for $1.93 million, plus 640,000 shares through purchase agreements. The voting/put arrangement around the July 31 special meeting ended after the proposals failed.	Existing-control and financing signal. Only the open-market portion is a clean buy; the purchase-agreement shares and failed meeting change the governance context.
PBT — SoftVest (Schedule 13D/A)	SoftVest reported 6,217,107 units, or 13.3%, alongside the July 28 combination agreement. The filing also describes voting support and a rights-offering backstop of up to $71.16 million with Horizon Kinetics.	Deal-linked alignment, not a completed $71.16 million purchase. The backstop is a conditional maximum.
STIM — Jorey Chernett (Schedule 13D/A)	Chernett reported 10,588,988 shares, or 15.22%, with an aggregate purchase price of approximately $20.68 million. An August 3 framework allows him to recommend a board candidate if a director seat opens, subject to the stated approvals. The amendment became available before the cutoff on August 4.	Governance leverage. This is more useful as a board-right and influence watch than as proof of a new week-specific buy.
GALT — Richard Uihlein (Schedule 13D/A)	Uihlein reported 54,673,646 shares, or about 49.30%, including securities underlying warrants, options, and convertibles. On July 31, roughly $105.8 million of debt was converted into 34,376,167 common shares.	Capital-structure dilution and control concentration. It is not an open-market purchase, even though the ownership percentage rose.
LQDA — Farallon (Schedule 13G/A)	Farallon reported 8,365,038 shares, or 9.4%, in a filing available August 4. The position was measured as of June 30 and reported as passive.	Ownership map, not a current-week trade. Without a prior share count or transaction schedule, the filing cannot tell us whether Farallon bought or sold during this window.
ASMB — Farallon (Schedule 13G/A)	Farallon reported 1,604,590 shares, or 8.1%, also measured at June 30. 1,020,410 warrants were excluded under the filing's 4.99% ownership cap and 60-day test.	Second passive biotech map. The warrant exclusion is a reminder not to treat the reported common-share percentage as the holder's entire economic exposure.
VTVT — Millennium / Integrated Core Strategies (Schedule 13G/A)	Millennium entities reported 269,874 shares, or 6.9%; Integrated Core Strategies reported 249,027 shares, or 6.3%. Both positions were measured at June 30 and filed as passive.	A signal about ownership concentration in a small biotech, not evidence of a July trade. The two reporting groups should not be combined without proving their holdings are non-overlapping.

Sector and theme read

The week's concentration was structural rather than macroeconomic:

Closed-end funds and alternative structures led the directional tape. Saba's ECAT, IIF, BPRE, and ASA disclosures all revolve around discounts, control, governance, or a change in fund structure. This is a different signal from a fund manager rotating into a sector ETF or a group of operating companies.
Biotech and healthcare produced several threshold disclosures, but not a clean buy basket. LQDA, ASMB, VTVT, and STIM all put healthcare names on the screen. Only STIM came with an explicit governance framework; the Farallon and Millennium filings are passive snapshots measured June 30.
Special situations supplied the headline caveats. PBT is merger-linked, UUU mixes open-market shares with purchase agreements and a failed vote, and GALT is a debt conversion. These can matter materially to shareholders while still being the wrong data type for a simple “whale bought X shares this week” ranking.

The retail filter for this week

Most actionable direction: start with ECAT, then IIF. Both filings describe open-market activity; still, their aggregate costs are cumulative, not weekly dollar flows.
Most important catalyst risk: Saba's BPRE governance language and ASA's restructuring proposal. The next useful evidence is a board response, formal proposal, proxy filing, or a clearly dated transaction—not the headline percentage alone.
Do not copy the passive maps as trades: Farallon and Millennium report positions measured at June 30. They tell you where ownership stood, not what the managers did between July 28 and August 4.
Separate equity mechanics from conviction: Uihlein's GALT position grew through debt conversion, while SoftVest's PBT backstop is conditional. Neither is equivalent to a cash purchase in the open market.

Bottom line

This was a Saba-led activism and structure week, not a broad “smart money is buying healthcare” week. The cleanest directional evidence sits in Saba's late-July ECAT and IIF activity; the larger dollar figures elsewhere mostly describe existing positions, control rights, restructuring proposals, or financing mechanics. For the next update, the highest-value follow-through is whether the Saba filings produce concrete governance action—and whether ECAT or IIF show another dated open-market tranche.